Medical Innovation Exchange

Jiving with Jazz after $325M opt-in, Zymeworks links HER2 bispecific to 84% survival after 18 months

https://www.fiercebiotech.com/biotech/jiving-jazz-after-325m-opt-zymeworks-links-her2-bispecific-84-survival-after-18-months

Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!